Business Wire

TX-MARY-KAY

15.9.2022 17:06:38 CEST | Business Wire | Press release

Share
Mary Kay Challenges Global Youth to Address SDG 14: Life Below Water in Third Annual Network for Teaching Entrepreneurship World Series of Innovation Challenge

Mary Kay Inc., a leading corporate advocate of women’s empowerment and entrepreneurship, announces its third annual World Series of Innovation (WSI) challenge in partnership with Network for Teaching Entrepreneurship (NFTE). The global competition invites young people ages 13-24 to put their critical thinking skills to the test and get involved in solving some of the biggest challenges humanity faces today to advance the UN Sustainable Development Goals (SDGs).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220915005847/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Network for Teaching Entrepreneurship an international nonprofit organization providing entrepreneurship training and educational programs to middle and high school students, college students, and adults (Graphic: Network for Teaching Entrepreneurship)

Mary Kay’s WSI challenge kicks off September 15 in conjunction with World Clean Up Day. The Mary Kay challenge encourages young entrepreneurs to submit innovative solutions to address UN SDG 14: Life Below Water. Specifically, students are challenged to design a solution to further the conservation and/or protection of the world’s marine ecosystems and coastal communities.

“All life on Earth began in and depends on our oceans. Water is the most valuable resource on our planet, and it’s essential that we not only respect it, but do our part to protect it,” said Deborah Gibbins, Chief Operating Officer for Mary Kay Inc. “The next generation of global thinkers and leaders are already addressing these critical areas of concern and spearheading conservation efforts. We are excited to see how the world’s youth can help to advance ecosystems and biodiversity conservation globally.”

In its first year partnering with the NFTE World Series of Innovation in 2020, Mary Kay sponsored a WSI challenge for UN SDG 12: Responsible Consumption and Production. Young entrepreneurs were encouraged to design a product, service or initiative that promoted the reuse or upcycling of textiles. In 2021, Mary Kay sponsored its second WSI challenge to address UN SDG 5: Gender Equality. Students were tasked with developing programs to promote workplace equality and ensure equal access to economic opportunity for women and girls.

“Mary Kay Global Oceans Conservations Challenge dares our young WSI competitors to think big about water quality,” said Dr. J.D. LaRock, President and CEO of NFTE. “In classrooms, students learn that water is fundamental to a healthy ecosystem. Through experiences like WSI, however, they become empowered to sustain that resource. They can ideate ways to look after marine life, safeguard oceans, secure affordable access to clean drinking water, protect water resources from pollution, address overconsumption, or otherwise help preserve our ecosystem for generations to come. That’s powerful.”

NFTE is a global educational non-profit focused on bringing the power of entrepreneurship to low-income communities. Since its founding more than 35 years ago, NFTE has trained thousands of teachers and educated well over a million young people worldwide. Every fall, NFTE launches a new set of challenges for the WSI competition and invites corporate sponsors to address the UN SDGs. The 2022 NFTE World Series of Innovation is presented by Citi Foundation and features challenges sponsored by Mary Kay Inc., MetLife Foundation, Mastercard, Bank of the West, Link, Maxar, Ernst & Young, LLP (EY), ServiceNow and Zuora. The top three winners will be announced in early 2023.

For more information on the World Series of Innovation and all challenges, visit https://innovation.nfte.com/.

About Mary Kay

One of the original glass ceiling breakers, Mary Kay Ash founded her dream beauty company in 1963 with one goal: enriching women’s lives. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in nearly 40 countries. As an entrepreneurship development company, Mary Kay is committed to empowering women on their journey through education, mentorship, advocacy, networking, and innovation. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skincare, color cosmetics, nutritional supplements, and fragrances. Mary Kay believes in enriching lives today for a sustainable tomorrow, partnering with organizations from around the world focusing on promoting business excellence, supporting cancer research, advancing gender equality, protecting survivors from domestic abuse, beautifying our communities, and encouraging children to follow their dreams. Learn more at marykayglobal.com, find us on Facebook, Instagram, and LinkedIn, or follow us on Twitter.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220915005847/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro

Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a

Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release

Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere

The Premier Jumping League (PJL) Launches with a Record-Breaking $300 Million Guaranteed Prize Pot, Defining a New Era for Showjumping30.3.2026 11:00:00 CEST | Press release

The PJL empowers riders to compete as full-time professional athletes while working towards a sustainable economic model for the sport. Backed by McCourt Global and shaped by a leadership team with decades of experience in equestrian competition, sport, and entertainment, the PJL sets a new, sustainable, and globally relevant standard for elite jumping. Sixteen teams will compete across fourteen iconic international venues throughout Europe, North America, and the Middle East when the inaugural season opens in March 2027. The Premier Jumping League (PJL) launches with a record-breaking $300 million guaranteed prize pot, defining a new era for showjumping. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330990938/en/ Photography credits: Daniel Benson for The Premier Jumping League/ Wieden+Kennedy London Backed by McCourt Global and its Executive Chairman, Frank McCourt, the PJL is a groundbreaking global competition that e

Dompé Announces First Patient Enrolled in New Study of Intranasal NGF in Cerebral Palsy30.3.2026 11:00:00 CEST | Press release

Cerebral Palsy (CP) refers to a group of permanent disorders in the development of movement and posture, which causes activity limitations, and is attributed to non-progressive disturbances that occurred in the developing fetal or infant brain.1 Nerve growth factor (NGF) is a naturally-occurring protein that supports damaged nerve cells and improves nervous system signaling, Dompé is investigating whether intranasal NGF has the potential to improve movement and neurodevelopment and address underlying brain damage in people with CP. Dompé’s intranasal NGF platform builds on the Nobel Prize-winning discovery of neurobiologist Professor Rita Levi-Montalcini and biochemist Dr. Stanley Cohen. Dompé, a leading biopharmaceutical company with operations in Italy and in the U.S., announced that the first patient has been enrolled at the Agostino Gemelli IRCCS University Hospital in Rome, Italy, in a Phase 2 investigational study of an intranasal form of Nerve Growth Factor (NGF) (Cenegermin-bkb

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye